WO2010062715A3 - Polymorphs of dasatinib and process for preparation thereof - Google Patents

Polymorphs of dasatinib and process for preparation thereof Download PDF

Info

Publication number
WO2010062715A3
WO2010062715A3 PCT/US2009/062966 US2009062966W WO2010062715A3 WO 2010062715 A3 WO2010062715 A3 WO 2010062715A3 US 2009062966 W US2009062966 W US 2009062966W WO 2010062715 A3 WO2010062715 A3 WO 2010062715A3
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
preparation
polymorphs
solvates
methods
Prior art date
Application number
PCT/US2009/062966
Other languages
French (fr)
Other versions
WO2010062715A2 (en
Inventor
Pavel Vraspir
Ales Gavenda
Roman Gabriel
Alexandr Jegorov
Original Assignee
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Usa, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceutical Usa, Inc filed Critical Teva Pharmaceutical Industries Ltd.
Publication of WO2010062715A2 publication Critical patent/WO2010062715A2/en
Publication of WO2010062715A3 publication Critical patent/WO2010062715A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides solvates of Dasatinib, crystalline forms of Dasatinib solvates and methods of their preparation.
PCT/US2009/062966 2008-11-03 2009-11-02 Polymorphs of dasatinib and process for preparation thereof WO2010062715A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11073508P 2008-11-03 2008-11-03
US61/110,735 2008-11-03

Publications (2)

Publication Number Publication Date
WO2010062715A2 WO2010062715A2 (en) 2010-06-03
WO2010062715A3 true WO2010062715A3 (en) 2010-11-18

Family

ID=41402056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/062966 WO2010062715A2 (en) 2008-11-03 2009-11-02 Polymorphs of dasatinib and process for preparation thereof

Country Status (1)

Country Link
WO (1) WO2010062715A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010067374A2 (en) * 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
CN101891738B (en) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 Dasatinib polymorph and preparation method and medical composition thereof
AU2011284341A1 (en) 2010-07-30 2013-02-21 Ranbaxy Laboratories Limited N-Methylformamide solvate of dasatinib
CN102030745B (en) * 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib solvate and preparation method thereof
CN102643275B (en) * 2011-02-21 2016-04-20 江苏先声药物研究有限公司 The preparation method that a kind of Dasatinib N-6 crystal formation is new
CN102898424A (en) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 Novel polymorphs of dasatinib, and preparation method thereof
WO2013065063A1 (en) 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use
ES2637829T3 (en) * 2012-06-15 2017-10-17 Basf Se Multi-component crystals comprising dasatinib and selected co-crystal forming agents
MX2016001096A (en) 2013-07-25 2016-04-25 Basf Se Salts of dasatinib in amorphous form.
AU2014295144B2 (en) 2013-07-25 2017-06-15 Basf Se Salts of Dasatinib in crystalline form
CA2950485A1 (en) 2014-06-30 2016-01-07 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
WO2018078392A1 (en) 2016-10-29 2018-05-03 Cipla Limited Polymorphs of dasatinib
CN111108104A (en) 2017-07-07 2020-05-05 拜康有限公司 Polymorphic forms of dasatinib
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077945A2 (en) * 2004-02-06 2005-08-25 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007035874A1 (en) * 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077945A2 (en) * 2004-02-06 2005-08-25 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007035874A1 (en) * 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof

Also Published As

Publication number Publication date
WO2010062715A2 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2010062715A3 (en) Polymorphs of dasatinib and process for preparation thereof
HK1210137A1 (en) Process for the preparation of 2,3,3,3-tetrafluoropropene 2333-
WO2009067674A3 (en) Polymorphs of sunitinib base and processes for preparation thereof
HK1153728A1 (en) Process for the preparation of 2,3,3,3-tetrafluoropropene 2333-
ZA201007526B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene
WO2010014883A3 (en) Azacitidine process and polymorphs
WO2010122578A3 (en) Process for preparation of sitagliptin and its intermediates
WO2008066935A3 (en) Crystalline forms of tigecycline and processes for preparation thereof
EP2305667A3 (en) Nilotinib intermediates and preparation thereof
HK1201822A1 (en) Process for the preparation of 5,6-dihydro-1h-pyridin-2-one compounds 56--1h--2-
WO2007109654A3 (en) Docetaxel polymorphs and processes
WO2010078396A3 (en) Compounds, intermediates, and methods of preparing the same
WO2009067578A3 (en) New vitamin d receptor activators and methods of making
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2011091131A3 (en) Eslicarbazepine acetate and its polymorphs
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
WO2009137714A3 (en) Forms of lapatinib ditosylate and processes for preparation thereof
WO2010011834A3 (en) Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs
AU2009254929A8 (en) An improved process for the preparation of amines
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2010016931A3 (en) Polymorphs of fluticasone furoate and process for preparation thereof
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2010027848A3 (en) Forms of lapatinib compounds and processes for the preparation thereof
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
SI2044099T1 (en) Process for the preparation of s-fluoromethyl-6 ,9 -difluoro-11 -hydroxy-16 -methyl-17 -propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09753276

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09753276

Country of ref document: EP

Kind code of ref document: A2